

HyperSciences Q1 2024 Update



I am pleased to share that we have met major milestones in commissioning our new HyperCore 50 for our Phase 2 HyperDrill™ HTBM - Hyper Tunnel Boring and Mining system testing for our Confidential Major Mining Partner and made significant progress with our Baffle Tube Ram Accelerator ("BTRA") technology! We commissioned a new Ramac 50 mm tube in our HyperLab, and the tests have been overwhelmingly successful. In fact, we are now too high-energy to go much further without field trials.




Figure 1: HyperSciences' Baffle Tube Ram Accelerator (BTRA)

With this progress, HyperSciences is ready to launch the next phase of our major mining contract field test, and we are seeking additional funding of up to \$500,000 to provide capital needed to purchase additional ram accelerator gear, engineering, and tech support for testing. (See more on investment opportunities below.) Our Confidential Major Mining Partner has indicated an interest in committing significant additional funds when we successfully demonstrate our technology's ability to achieve our targeted 1/3 tonne rock per shot over 50 consecutive shots. We believe that this public sponsorship could significantly increase our company's value and help pave the way for us to proceed with our plans to list on NASDAQ.

Due to our team's amazing work and the breakthroughs we've made to advance our BTRA technology over this past quarter, I am confident in our ability to exceed our Confidential Major Mining Partners' expectations for breaking rock this summer!



Figure 2: HyperLab with new 50 mm Baffle Tube Ram Accelerator (BTRA)

Dual-Use Technological Advantage! Mining and Aerospace demos.

As we have shared in past updates, the ram accelerator technology is a dual-use technology applicable to subterranean terrestrial and aerospace use cases such as drilling, mining, and tunneling, as well as aerospace and defense markets. Our exclusive patent license agreement with the University of Washington (UW) covers 7 BTRA patents. It requires that we concurrently develop and test our <100 km aerospace-level prototypes over the next year alongside the commercialization of our mining and tunneling applications. To this end, Pipeline2Space, Inc. (P2S) has been an important partner, providing an additional \$700,000 directly to HyperSciences in co-development funding in 2022 and 2023. We are maximizing efficiency by leveraging P2S's funding to drive further progress and expect to do so again with additional partner funding in 2024.

Webinar Invitation:

Please join President & CEO, Mark Russell for a HyperSciences' update to hear the latest developments. **CLICK HERE** to register for the webinar on June 19, 2024, at 11:30 am Pacific (2:30 pm Eastern) to learn about all the progress that has been occurring at HyperSciences and how we are partnering with Pipeline2Space.

You are welcome to visit <https://invest.pipeline2space.com> and/or come to the webinar to learn more about our 50 mm system being upgraded to fly longer aerospace projectiles to the edge of space at Spaceport America.

Our current 50 mm system is operational daily as a prototype BTRA system. As we advance the 50 mm technology, we are also unlocking short-term and long-term opportunities in defense and aerospace. By initially focusing on horizontal flight, we are strategically positioning ourselves to achieve significant milestones on Earth and aerospace. These collaborative efforts pave the way for substantial advancements in our defense and with space applications. To this end HyperSciences and Pipeline2Space have begun meetings and discussions with divisions in the Department of Defense and prominent defense companies.

Invitation to Invest

HyperSciences has a Reg D convertible note offering open and available to accredited investors. The financing documents can be found on our website or by emailing investor@hypersciences.com. The minimum investment is \$20,000, with 10% interest and the opportunity to convert to stock at a 25% discount upon listing on a stock exchange. The conversion to stock is at the discretion of each investor. Feel free to contact us with any questions.

The financing will help fund the next phase of our project this summer, which aims to advance our major mining partnership and secure larger contracts with our customers and others. Additionally, I wanted to make you aware that Pipeline2Space is currently conducting its own Reg CF financing that will be closing within the next few months. As you are aware, I am CEO of both companies and HyperSciences' investors are not owners of Pipeline2Space. If you are interested in investing directly into Pipeline2Space, please go to <https://invest.pipeline2space.com> for additional information on the offering.

I look forward to sharing more about our progress with you at the next investor webinar on June 19, 2024. Come to the webinar to learn how HyperSciences might partner with P2S to get the most value for HyperSciences investors for all cases <100 km with dual technology subterranean geothermal energy drilling, tunneling, and in-atmosphere aerospace and defense.

Thanks,
Mark Russell
President & CEO/ Founder- HyperSciences, Inc.

Investor Contact

Rich Matthews, Managing Partner
Integrous Communications
Mobile: +1 604-355-7179
rmatthews@integcom.us



About HyperSciences

Founded in 2014, HyperSciences develops and builds innovative hypervelocity technologies intended for major industries such as fast tunneling, energy drilling and aerospace. HyperSciences has offered securities under Regulation Crowdfunding and Tier II of Regulation A, and is subject to ongoing reporting obligations. You can access these reports and other securities filings on [EDGAR](#). HyperSciences has a Reg D 506(c) offering of securities open for accredited investors.

Relationship with Pipeline2Space

The Company entered into a services agreement with Pipeline2Space, Inc. ("P2S") for certain collaborative research and development services to P2S in exchange for a flat monthly fee. The services agreement provided for P2S to pay Company \$100,000 a month for collaborative research and development activities. P2S paid Company \$600,000 during 2022 and \$100,000 during 2023 which was recognized as a contra-research and development expense in the consolidated statement of operations for 2022 and 2023.

Our CEO (Mark Russel) is also the CEO of P2S which continues long-term development of similar, but much longer accelerator aerospace technology to launch small spacecraft (and later much larger) to lofted trajectories for single or multiple stage orbital insertion. P2S is a sister company to HyperSciences in that EnergeticX.net, L.L.C. owns the majority of Pipeline2Space's shares and is the also largest shareholder of HyperSciences.

Legal Disclaimer

This email may include "forward-looking statements." To the extent that the information presented in this presentation discusses financial projections, information, or expectations about HyperSciences, Inc. (the "Company" or "HyperSciences") business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes."

Although HyperSciences believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Forward-looking statements speak only as of the date of the document in which they are contained, and HyperSciences does not undertake any duty to update any forward-looking statements except as may be required by law. Please review HyperSciences' filings on EDGAR to learn more about the principal risks, uncertainties, assumptions, and other important factors that could cause actual results to differ materially from any forward-looking statements.

HyperSciences is currently undertaking a private placement offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The offering documents relating to each offering of equity interests by the Company will contain this and other information concerning the Company, including risk factors, which should be read carefully before investing. Securities of the Company are being offered and sold in reliance on exemptions from registration under the Securities Act. In accordance therewith, you should be aware that (i) the securities may be sold only to "accredited investors," as defined in Rule 501 of Regulation D; (ii) the securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission (the "SEC") will not pass upon the merits of or give its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials; (iv) the securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; investing in these securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. The offering documents may include "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to the risks and uncertainties set forth in the attached materials, which could cause actual results to differ materially from the anticipated results set forth in such forward-looking statements. Any forward-looking statement made by us speaks only as of the date on which it is made, and we undertake no obligation to publicly update any forward-looking statement except as may be required by law.

The Company is "Testing the Waters" under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. Any person's indication of interest involves no obligation or commitment of any kind. The information in that offering statement will be more complete than the information the Company is providing now, and could differ materially. You must read the documents filed. No offer to sell the securities or solicitation of an offer to buy the securities is being made in any state where such offer or sale is not permitted under the "blue sky" or securities laws thereof. No offering is being made to individual investors in any state unless and until the offering has been registered in that state or an exemption from registration exists therein. The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. The contents of this email are not to be construed as legal, financial or tax advice.

Information about the Company and its business plan herein is presented in summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This email does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold within the United States, unless an exemption from such registration is available.

Copyright © 2024, HyperSciences, Inc. All rights reserved.

Our mailing address is:

1314 S Grand Blvd Ste 2-133

Spokane, WA 99202

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

